Additional file 1: of Safety and efficacy of infliximab in the treatment of refractory uveoretinitis in Behçet’s disease: a large-scale, long-term postmarketing surveillance in Japan

Figure S1. Re-infusion of IFX in patients with BD who developed IRs. Table S1. Independent factors associated with any infections and efficacy. Table S2. Safety profile of IFX therapy in patients with BD, RA, Crohn’s disease (CD) or psoriasis (PsO) in the Japanese PMS study. (PDF 151 kb